Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

What Was Tested

This randomized controlled trial paper looks at Glucagon and Liraglutide.

Glucagon-like peptide 1 (GLP-1) is a potent glucose-lowering agent of potential interest for the treatment of type 2 diabetes.

A standardized mixed meal was served at 1130 h.

Who Took Part

According to the abstract, 11 patients were involved.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the patients nor the staff measuring them knew who was on Glucagon, so expectations could not easily colour the readings.

Some patients received a placebo instead of Glucagon, giving a reference point.

In the crossover set-up each of the patients took both Glucagon and the comparison in turn, acting as their own control.

What Was Measured

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 2, Fasting, Glucagon, Glucagon-Like Peptide 1, Homeostasis and Insulin.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon and Liraglutide in 11 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2002 (Diabetes), a journal based in United States.

More context: the Glucagon compound page and the Liraglutide compound page.